title: Chimeric antigen receptor T-cell immunotherapy tackles blood cancers.
authors.forename: Vicki
authors.initials: V
authors.lastname: Brower
mesh_terms: D018033:Antibodies, Bispecific / Q000276:immunology / Q000627:therapeutic use; D018941:Antigens, CD19 / Q000187:drug effects / Q000276:immunology*; D000970:Antineoplastic Agents / Q000276:immunology* / Q000627:therapeutic use*; D018014:Gene Transfer Techniques; D019337:Hematologic Neoplasms / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology / Q000628:therapy; D008223:Lymphoma / Q000276:immunology / Q000628:therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000276:immunology / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000628:therapy; D009965:Orphan Drug Production; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000628:therapy; D011948:Receptors, Antigen, T-Cell / Q000276:immunology* / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D018033:Antibodies, Bispecific; D018941:Antigens, CD19; D000970:Antineoplastic Agents; C000598123:CTL019 chimeric antigen receptor; D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins; C510808:blinatumomab